Sugi Predict

Sugi Predict / Compounds / SCHEMBL4239042

SCHEMBL4239042

SCHEMBL4239042

Nc1cccc(Nc2cc(Nc3cccc(C(F)(F)F)c3)ncn2)c1

nearest known ligand 0.68

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ THRB P10828 1/20 0.68
▸ EGFR P00533 8/20 0.61
▸ ERBB4 Q15303 1/20 0.61
▸ KDM4E B2RXH2 2/20 0.59
▸ ABCG2 Q9UNQ0 1/20 0.54
▸ AURKA O14965 2/20 0.53
▸ TSHR P16473 2/20 0.53
▸ HTT P42858 1/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ BTK Q06187 2/20 0.52
▸ GAA P10253 2/20 0.51
▸ ALDH1A1 P00352 1/20 0.51
▸ MAPT P10636 1/20 0.51
▸ RAB9A P51151 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ TNNI3K Q59H18 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1387447 0.91 THRB (0.80) THRBEGFRERBB4KDM4EABCG2
SCHEMBL4239383 0.84 KDR (0.57) THRBEGFRTNNI3K
SCHEMBL374332 0.84 THRB (0.74) THRBEGFRERBB4KDM4EABCG2
SCHEMBL4235274 0.82 THRB (0.57) THRBEGFRERBB4KDM4EABCG2
SCHEMBL4234991 0.82 THRB (0.54) THRBEGFRERBB4KDM4EABCG2
SCHEMBL691596 0.82 MEN1 (0.67) EGFRKDM4ETSHRMAPK1GAA
SCHEMBL19420148 0.81 THRB (0.70) THRBEGFRERBB4KDM4EABCG2
SCHEMBL13778007 0.81 THRB (1.00) THRBEGFRERBB4KDM4EABCG2
SCHEMBL374140 0.81 THRB (0.70) THRBEGFRERBB4KDM4EABCG2
SCHEMBL3918204 0.81 EGFR (0.69) THRBEGFRKDM4EABCG2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181991-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC 2009-07-16 — — US claimed
EP-1943233-A2 COMPOUNDS AND COMPOSITIONS FOR PROTEIN KINASE INHBITORS IRM, LLC (BM) 2008-07-16 — — EP claimed
WO-2007056151-A2 PROTEIN KINASE INHBITORS IRM LLC (BM) 2007-05-18 — — WO claimed
US-12018280-B2 Method for freezing aggregates of pluripotent stem cell-derived cardiomyocytes KYOTO UNIVERSITY (JP) 2024-06-25 — — US disclosed
EP-3431584-B1 METHODS FOR FREEZING AN AGGREGATE OF PLURIPOTENT STEM CELL-DERIVED CARDIOMYOCYTES UNIV KYOTO (JP) 2023-06-28 — — EP disclosed
WO-2023286772-A1 CARDIOMYOCYTE PRODUCTION METHOD 三菱ケミカル株式会社 2023-01-19 — — WO disclosed
US-20200325448-A1 METHOD FOR FREEZING AGGREGATES OF PLURIPOTENT STEM CELL-DERIVED CARDIOMYOCYTES KYOTO UNIVERSITY (JP) 2020-10-15 — — US disclosed
EP-3150705-B1 METHOD FOR INDUCING MYOCARDIAL DIFFERENTIATION OF PLURIPOTENT STEM CELLS USING LOW-MOLECULAR COMPOUND UNIV KYOTO (JP) 2019-05-15 — — EP disclosed
EP-2966166-B1 PROMOTER OF DIFFERENTIATION OF PLURIPOTENT STEM CELL INTO MYOCARDIUM, WHICH COMPRISES EGF RECEPTOR INHIBITOR UNIV KYOTO (JP) 2019-04-03 — — EP disclosed
US-10233426-B2 Method for inducing cardiac differentiation of pluripotent stem cell with low-molecular compounds KYOTO UNIVERSITY (JP) 2019-03-19 — — US disclosed
US-10196609-B2 Composition for promoting cardiac differentiation of pluripotent stem cell comprising EGFR inhibitor KYOTO UNIVERSITY (JP) 2019-02-05 — — US disclosed
US-7982036-B2 4,6-disubstitued pyrimidines useful as kinase inhibitors AVILA THERAPEUTICS, INC. (US) 2011-07-19 — — US disclosed
WO-2010123870-A1 HETEROARYL COMPOUNDS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2010-10-28 — — WO disclosed
US-20100016296-A1 HETEROARYL COMPOUNDS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2010-01-21 — — US disclosed
US-20100016296-A1 HETEROARYL COMPOUNDS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2010-01-21 — — US disclosed
US-20090181991-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC 2009-07-16 — — US disclosed
US-20090137588-A1 HETEROARYL COMPOUNDS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2009-05-28 — — US disclosed
US-20090137588-A1 HETEROARYL COMPOUNDS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2009-05-28 — — US disclosed
EP-1943233-A2 COMPOUNDS AND COMPOSITIONS FOR PROTEIN KINASE INHBITORS IRM, LLC (BM) 2008-07-16 — — EP disclosed
WO-2007056151-A2 PROTEIN KINASE INHBITORS IRM LLC (BM) 2007-05-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10233426-B2 Method for inducing cardiac differentiation of pluripotent stem cell with low-molecular compounds SRC, MYLK2, YES1 THRB 1714/4885EGFR 10/4885ERBB4 30/4885
US-20090181991-A1 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS ERBB2, BMX, ERBB3 THRB 461/4885EGFR 42/4885ERBB4 19/4885
US-20200325448-A1 METHOD FOR FREEZING AGGREGATES OF PLURIPOTENT STEM CELL-DERIVED CARDIOMYOCYTES TNNI3, MYLK2, TNNT2 THRB 4050/4885EGFR 4837/4885ERBB4 4694/4885
US-20090137588-A1 HETEROARYL COMPOUNDS AND USES THEREOF ABCG2, CYP3A43, CYP3A5 THRB 3244/4885EGFR 1981/4885ERBB4 1903/4885
US-12018280-B2 Method for freezing aggregates of pluripotent stem cell-derived cardiomyocytes TNNI3, MYLK2, TNNT2 THRB 4050/4885EGFR 4837/4885ERBB4 4694/4885
US-20100016296-A1 HETEROARYL COMPOUNDS AND USES THEREOF ABCG2, CYP3A43, CYP3A5 THRB 3244/4885EGFR 1981/4885ERBB4 1903/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.